• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生理性纤维蛋白溶解机制。

Mechanisms of physiological fibrinolysis.

作者信息

Lijnen H R, Collen D

机构信息

Center for Molecular and Vascular Biology, K.U. Leuven, Belgium.

出版信息

Baillieres Clin Haematol. 1995 Jun;8(2):277-90. doi: 10.1016/s0950-3536(05)80268-9.

DOI:10.1016/s0950-3536(05)80268-9
PMID:7549063
Abstract

The fibrinolytic system comprises an inactive proenzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, which degrades fibrin. Two immunologically distinct plasminogen activators (PA) have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). t-PA mediated plasminogen activation is mainly involved in the dissolution of fibrin in the circulation, whereas u-PA mediated plasminogen activation mainly plays a role in pericellular proteolysis. Plasminogen activation is regulated by specific molecular interactions between its main components, such as binding of plasminogen and t-PA to fibrin, or to specific cellular receptors resulting in enhanced plasminogen activation, inhibition of t-PA and u-PA by plasminogen activator inhibitors (PAI) and inhibition of plasmin by alpha 2-antiplasmin. Controlled synthesis and release of PAs and PAIs primarily from endothelial cells also contributes to the regulation of physiological fibrinolysis. The lysine binding sites situated in the kringle structures of plasminogen play a crucial role in the regulation of fibrinolysis by modulating its binding to fibrin and to cell surfaces, and by controlling the inhibition rate of plasmin by alpha 2-antiplasmin.

摘要

纤维蛋白溶解系统包括一种无活性的前体酶,即纤溶酶原,它被纤溶酶原激活剂转化为活性酶纤溶酶,纤溶酶可降解纤维蛋白。已鉴定出两种免疫性质不同的纤溶酶原激活剂(PA):组织型纤溶酶原激活剂(t-PA)和尿激酶型纤溶酶原激活剂(u-PA)。t-PA介导的纤溶酶原激活主要参与循环中纤维蛋白的溶解,而u-PA介导的纤溶酶原激活主要在细胞周围蛋白水解中起作用。纤溶酶原激活受其主要成分之间特定分子相互作用的调节,例如纤溶酶原和t-PA与纤维蛋白或特定细胞受体的结合,导致纤溶酶原激活增强,纤溶酶原激活剂抑制剂(PAI)对t-PA和u-PA的抑制以及α2-抗纤溶酶对纤溶酶的抑制。主要来自内皮细胞的PA和PAI的受控合成和释放也有助于生理性纤维蛋白溶解的调节。位于纤溶酶原kringle结构中的赖氨酸结合位点在纤维蛋白溶解的调节中起关键作用,通过调节其与纤维蛋白和细胞表面的结合,并通过控制α2-抗纤溶酶对纤溶酶的抑制率。

相似文献

1
Mechanisms of physiological fibrinolysis.生理性纤维蛋白溶解机制。
Baillieres Clin Haematol. 1995 Jun;8(2):277-90. doi: 10.1016/s0950-3536(05)80268-9.
2
Elements of the fibrinolytic system.纤维蛋白溶解系统的组成部分。
Ann N Y Acad Sci. 2001;936:226-36. doi: 10.1111/j.1749-6632.2001.tb03511.x.
3
Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.与溶栓治疗相关的纤维蛋白溶解的分子基础。
Thromb Haemost. 1995 Jul;74(1):167-71.
4
Lipoprotein (a) regulates plasmin generation and inhibition.脂蛋白(a)调节纤溶酶的生成与抑制。
Chem Phys Lipids. 1994 Jan;67-68:363-8. doi: 10.1016/0009-3084(94)90158-9.
5
The Role of Fibrinolytic System in Health and Disease.纤维蛋白溶解系统在健康和疾病中的作用。
Int J Mol Sci. 2022 May 9;23(9):5262. doi: 10.3390/ijms23095262.
6
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.纤维蛋白溶解的分子机制及其在纤维蛋白特异性溶栓治疗中的应用。
J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202.
7
The fibrinolytic system in man.人类的纤维蛋白溶解系统。
Crit Rev Oncol Hematol. 1986;4(3):249-301. doi: 10.1016/s1040-8428(86)80014-2.
8
Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.通过在纤溶酶切割位点融合获得的嵌合型(组织型/尿激酶型)纤溶酶原激活剂的特性。
Thromb Haemost. 1993 May 3;69(5):466-72.
9
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.与纤维蛋白结合的1型纤溶酶原激活物抑制剂(PAI-1)与组织型纤溶酶原激活物(t-PA)或尿激酶型纤溶酶原激活物(u-PA)之间的相互作用。t-PA的指状结构域和kringle-2结构域介导t-PA/PAI-1复合物与纤维蛋白的结合。
J Clin Invest. 1989 Aug;84(2):647-55. doi: 10.1172/JCI114211.
10
Fibrin-specific thrombolytic agents.纤维蛋白特异性溶栓剂。
Klin Wochenschr. 1988;66 Suppl 12:15-23.

引用本文的文献

1
Micrometer-scale tPA beads amplify plasmin generation for enhanced thrombolytic therapy.微米级组织型纤溶酶原激活剂(tPA)微珠可增强纤溶酶生成,用于强化溶栓治疗。
Bioeng Transl Med. 2025 Mar 3;10(4):e70012. doi: 10.1002/btm2.70012. eCollection 2025 Jul.
2
Kringle-Dependent Inhibition of Plasmin-Mediated Fibrinolysis by Native and Citrullinated Core Histones.天然和瓜氨酸化核心组蛋白通过kringle结构域对纤溶酶介导的纤维蛋白溶解的抑制作用
Int J Mol Sci. 2025 Jun 17;26(12):5799. doi: 10.3390/ijms26125799.
3
A Bio-Adaptive Janus-Adhesive Dressing with Dynamic Lubrication Overlayer for Prevention of Postoperative Infection and Adhesion.
一种具有动态润滑覆盖层的生物适应性双面粘附敷料,用于预防术后感染和粘连。
Adv Sci (Weinh). 2025 May;12(18):e2500138. doi: 10.1002/advs.202500138. Epub 2025 Mar 20.
4
Endothelial senescence induced by PAI-1 promotes endometrial fibrosis.纤溶酶原激活物抑制剂-1诱导的内皮细胞衰老促进子宫内膜纤维化。
Cell Death Discov. 2025 Mar 6;11(1):89. doi: 10.1038/s41420-025-02377-0.
5
Harnessing micrometer-scale tPA beads for high plasmin generation and accelerated fibrinolysis.利用微米级组织型纤溶酶原激活剂(tPA)微珠实现高纤溶酶生成和加速纤维蛋白溶解。
bioRxiv. 2024 Nov 8:2024.11.06.621942. doi: 10.1101/2024.11.06.621942.
6
Association between Polymorphisms and Ischemic Stroke in a South Korean Case-Control Cohort.韩国病例对照队列研究中多态性与缺血性脑卒中的关联。
Int J Mol Sci. 2023 Apr 28;24(9):8041. doi: 10.3390/ijms24098041.
7
Direct delivery of plasmin using clot-anchoring thrombin-responsive nanoparticles for targeted fibrinolytic therapy.利用血栓锚定型凝血酶响应纳米颗粒直接递送纤溶酶用于靶向纤维蛋白溶解治疗。
J Thromb Haemost. 2023 Apr;21(4):983-994. doi: 10.1016/j.jtha.2022.11.037. Epub 2022 Dec 22.
8
Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation.内皮细胞表型,静脉血栓炎症的主要决定因素。
Front Cardiovasc Med. 2022 Apr 21;9:864735. doi: 10.3389/fcvm.2022.864735. eCollection 2022.
9
Association between Five Common Plasminogen Activator Inhibitor-1 () Gene Polymorphisms and Colorectal Cancer Susceptibility.五种纤溶酶原激活物抑制剂-1 () 基因多态性与结直肠癌易感性的关系。
Int J Mol Sci. 2020 Jun 18;21(12):4334. doi: 10.3390/ijms21124334.
10
Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.重组组织型纤溶酶原激活剂用于治疗顽固性前葡萄膜炎:病例系列
J Taibah Univ Med Sci. 2018 Apr 6;13(5):483-487. doi: 10.1016/j.jtumed.2018.03.005. eCollection 2018 Oct.